Table 1.
Baseline clinical and sociodemographic characteristics of the study population.
| Type of neoadjuvant treatment | ||||
|---|---|---|---|---|
| Total n = 99 (%) | CHT n = 52 (%) | CRT n = 47 (%) | ||
| Age at diagnosis | ||||
| >60 years, n(%) | 59 (59.6) | 33 (63.5) | 26 (55.3) | 0.410 |
| <=60 years, n(%) | 40 (40.4) | 19 (36.5) | 21 (44.7) | |
| Sex | ||||
| Male, n(%) | 81 (81.8) | 44 (84.6) | 37 (78.7) | 0.448 |
| Female, n(%) | 18 (18.2) | 8 (15.4) | 10 (21.3) | |
| ECOG performance status | ||||
| 0–1, n(%) | 98 (99.0) | 51 (98,1) | 47 (100.0) | 1.000 |
| 2, n(%) | 1 (1.0) | 1 (1.9) | 0 (0.0) | |
| Smoking status | ||||
| No smoke at diagnosis, n(%) | 49 (49.5) | 31 (59.6) | 18 (38.3) | 0.034 |
| Smoke at diagnosis, n(%) | 50 (50.5) | 21 (40.4) | 29 (61.7) | |
| T Stage (TNM 7th edition) | ||||
| cT1, n(%) | 28 (28.6) | 16 (30.8) | 12 (26.1) | 0.432 |
| cT2, n(%) | 36 (36.7) | 21 (40.4) | 15 (32.6) | |
| cT3, n(%) | 34 (34.7) | 15 (28.8) | 19 (41.3) | |
| Nodal station | ||||
| 1, n(%) | 59 (59.6) | 31 (59.6) | 28 (59.6) | 0.997 |
| >1, n(%) | 40 (40.4) | 21 (40.4) | 19 (40.4) | |
| Size of lymph nodes | ||||
| <3 cm, n(%) | 96 (97.0) | 50 (96.2) | 46 (97.9) | 1.000 |
| >=3 cm, n(%) | 3 (3.0) | 2 (3.8) | 1 (2.1) | |
| Histology | ||||
| Adenocarcinoma and others, n(%) | 55 (56.1) | 27 (51.9) | 28 (60.9) | 0.373 |
| Squamous, n(%) | 43 (43.9) | 25 (48.1) | 18 (39.1) | |
| Histopathologically-confirmed mediastinal lymph nodes | ||||
| No, n(%) | 42 (42.4) | 25 (48.1) | 17 (36.2) | 0.231 |
| Yes, n(%) | 57 (57.6) | 27 (51.9) | 30 (63.8) | |
| Type of surgery | ||||
| Pneumonectomy, n(%) | 15 (15.2) | 9 (17.3) | 6 (12.8) | 0.529 |
| Lobectomy, n(%) | 84 (84.8) | 43 (82.7) | 41 (87.2) | |
| Adjuvant chemotherapy | ||||
| No, n(%) | 76 (76.8) | 36 (69.2) | 40 (85.1) | 0.062 |
| Yes, n(%) | 23 (23.2) | 16 (30.8) | 7 (14.9) | |
| Adjuvant radiotherapy | ||||
| No, n(%) | 68 (68.7) | 22 (42.3) | 46 (97.9) | 0.000 |
| Yes, n(%) | 31 (31.3) | 30 (57.7) | 1 (2.1) | |
| RT treatment interruptions (neoadjuvant/adjuvant)a | ||||
| No interruption, n(%) | 64 (87.7) | 21 (80.8) | 43 (91.5) | 0.266 |
| Interruption <1week, n(%) | 9 (12.3) | 5 (19.2) | 4 (8.5) |
RT, radiotherapy; CHT, chemotherapy; CRT, chemoradiotherapy; ECOG, Eastern Cooperative Oncology Group.
Bold values signifies statistically significant results.
a
Unknown data of interruptions in 4 patients who received PORT.